What changed: Follicular lymphoma

When this page itself was last checked or edited.

Secondary haematologic malignancies; EZH2 leaves the FL armamentarium.

Accelerated approval in follicular lymphoma

R/R follicular lymphoma after ≥2 lines (accelerated)

Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)

R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)

A milestone in how this cancer is treated.

Relapsed or refractory follicular lymphoma after two or more lines, conditional

R/R follicular lymphoma after ≥2 lines (accelerated)

Relapsed or refractory follicular lymphoma after two or more lines

Relapsed/refractory follicular lymphoma

Off-the-shelf CD20×CD3 with ~60% CR in third line.

Relapsed/refractory follicular lymphoma (ZUMA-5)

Relapsed marginal zone lymphoma and follicular lymphoma

Axicabtagene (ZUMA-5) approved; tisagenlecleucel (ELARA) 2022; lisocabtagene 2024.

Accelerated approval, follicular lymphoma

Lenalidomide-rituximab matches chemo-immunotherapy first line.

Relapsed follicular lymphoma after ≥2 therapies

A milestone in how this cancer is treated.

Two years of maintenance doubles PFS after chemo-immunotherapy.

Consolidation after first-line chemotherapy in previously untreated follicular NHL

Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008

A milestone in how this cancer is treated.

Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma

Relapsed follicular lymphoma; first antibody approved for cancer

First monoclonal antibody for cancer, in relapsed indolent lymphoma.

Tsujimoto and Croce clone the breakpoint; BCL2 becomes the first anti-apoptotic oncogene.